Profound Medical Corp.

TSX:PRN.TO

Medical - Devices

Healthcare
$9.83 +1.18%

+$0.11 today

Market cap
$360.04M
Beta
0.52
P/E (TTM)
-6.3
EPS (TTM)
-$1.07
52W Low $5.23High $12.40

Volume 0.00M

Average 0.01M

PRN.TO EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Profound Medical Corp.TSX: PRN.TO

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$7.79M, compared with -$11M a year earlier. Trailing-twelve-month EBITDA was -$36.45M.

Context

  • EBITDA amounted to 252.8% of revenue in FY2025, down 48.0 pp from a year earlier.
  • EBITDA grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of -$26.4M (+36.2%) for the fiscal year ending Dec 2026, a step up from the -28.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$7.79M-5.7% QoQ
Last fiscal yearDec 2025
-$41.41M-28.9% YoY
LTMMar 2026
-$36.45M-1.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+29.2%+36.1%+6.9 pp
1 year-28.9%+36.2%+65.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(41.41M) USD
Year-over-year change
-28.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How PRN.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -1.4% is the 4th highest of 6, against a peer median of +21.8%.
  • EBITDA amounts to 194.3% of revenue for PRN.TO, versus a peer median of 27.9%.
PRN.TO Competitors
EBITDA for PRN.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DR.TOMedical Facilities CorporationLTM Mar 2026$75.52M USD-3.6%+5.1%24.7%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$49.15M CAD+45.8%—31.0%
CRRX.TOCareRx CorporationLTM Mar 2026CA$30.12M CAD+25.2%—8.0%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$17.79M USD+21.8%+0.0%31.9%
PRN.TOProfound Medical Corp.LTM Mar 2026-$36.45M USD-1.4%—194.3%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026-$44.63M USD-141.2%——
Peer median (excluding PRN.TO) —+21.8%+2.6%27.9%

Competitors are the stored peer set for PRN.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.87M6.68M7.2M10.68M16.38M
Cost of Revenue3.92M3.66M2.82M3.64M4.79M
Gross Profit2.95M3.02M4.38M7.04M11.59M
Gross Margin43.0%45.2%60.9%65.9%70.8%
Research & Development15.28M14.69M14.38M16.97M20.96M
Selling, General & Admin17.97M17.93M18.62M23.13M32.61M
Operating Expenses33.24M32.62M33M40.1M53.57M
Depreciation & Amortization1.88M1.6M929K936K569.8K
EBITDA(28.65M)(26.6M)(27M)(32.13M)(41.41M)
EBITDA Margin-416.8%-398.2%-375.0%-300.8%-252.8%
Operating Income(30.29M)(29.6M)(28.62M)(33.06M)(41.98M)
Operating Margin-440.7%-443.1%-397.5%-309.6%-256.3%
Interest Income205K1.06M1.64M1.44M1.09M
Interest Expense67K168.82K770K00
Other Income / Expenses(303K)1.22M200K5.24M(1.08M)
Income Before Tax(30.59M)(28.38M)(28.7M)(27.82M)(43.06M)
Pre-Tax Margin-445.1%-424.8%-398.6%-260.5%-262.9%
Income Tax Expense105K287K(128K)(2K)256.41K
Net Income(30.7M)(28.67M)(28.57M)(27.82M)(43.32M)
Net Margin-446.7%-429.1%-396.8%-260.4%-264.4%
EPS (Basic)(1.50)(1.38)(1.35)(1.12)(1.43)
EPS (Diluted)(1.50)(1.38)(1.35)(1.12)(1.43)
Weighted Avg Shares20.46M20.77M21.18M24.77M30.23M
Weighted Avg Shares (Diluted)20.47M20.77M21.18M24.77M30.23M

Profound Medical Corp.

TSX:PRN.TO

Intrinsic Alpha fair value

Locked

Current Price

$9.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.